INT31572

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1988
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 21
Total Number 22
Disease Relevance 16.49
Pain Relevance 1.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (FLT1) endosome (FLT1) Golgi apparatus (FLT1)
cytoplasm (FLT1) extracellular space (FLT1) extracellular region (FLT1)
Anatomy Link Frequency
plasma 2
muscle 2
blood 1
cleavage 1
endothelium 1
FLT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 25 99.74 Very High Very High Very High
Desipramine 2 98.10 Very High Very High Very High
antidepressant 2 97.86 Very High Very High Very High
cINOD 2 97.84 Very High Very High Very High
Morphine 2 96.80 Very High Very High Very High
peripheral neuropathy 5 94.36 High High
nud 4 82.00 Quite High
Pain 16 71.28 Quite High
abdominal pain 5 66.88 Quite High
headache 8 65.60 Quite High
Disease Link Frequency Relevance Heat
Toxicity 36 99.62 Very High Very High Very High
Pancreatic Cancer 77 99.28 Very High Very High Very High
Fibromyalgia 15 99.08 Very High Very High Very High
Disease 122 99.04 Very High Very High Very High
Camurati-engelmann Disease 24 98.88 Very High Very High Very High
Breast Cancer 94 97.82 Very High Very High Very High
INFLAMMATION 21 97.74 Very High Very High Very High
Peripheral Neuropathy 5 94.36 High High
Ovarian Cancer 404 94.24 High High
Thyroid Disease 8 94.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This was sufficient to elevate the fractional occupancy of total sVEGFR1 (e.g., +9%) despite decreasing free sVEGFR1; yet not enough to prevent overall reductions in bound fraction of total VEGF (e.g., -14%) because of the greater increase in free VEGF.
Negative_regulation (decreasing) of sVEGFR1
1) Confidence 0.48 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.06 Pain Relevance 0
However, a phase II trial in breast cancer provided no evidence of clinical activity [111], although there was evidence of biological activity, with a decrease in serum VEGFR1 levels.
Negative_regulation (decrease) of VEGFR1 associated with breast cancer
2) Confidence 0.42 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.62 Pain Relevance 0
The down-regulation of Flt-1 in the placental bed may result in a decreased maternal vascular adaptation to pregnancy [27].
Negative_regulation (regulation) of Flt-1
3) Confidence 0.42 Published 2008 Journal BMC Med Genet Section Body Doc Link PMC2496902 Disease Relevance 0.17 Pain Relevance 0
This type of toxicity was not seen with reduced FLT doses.
Negative_regulation (reduced) of FLT associated with toxicity
4) Confidence 0.36 Published 2007 Journal BMC Nucl Med Section Body Doc Link PMC1931583 Disease Relevance 1.18 Pain Relevance 0.08
Secondly, the transendothelial gradient of sVEGFR1 at control favored net extravasation, hence increasing kP resulted in: lower plasma concentrations of free sVEGFR1; as well as increased free sVEGFR1 in the interstitium facing the endothelium where kP was upregulated, at the expense of a decrease in interstitial free sVEGFR1 in the other tissue compartment (e.g., “Control” vs.
Negative_regulation (decrease) of sVEGFR1 in endothelium
5) Confidence 0.35 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
At the control secretion rates of VEGF and sVEGFR1 needed to reproduce these selected plasma concentrations, our predicted interstitial concentrations ([V]IS?
Negative_regulation (rates) of sVEGFR1 in plasma
6) Confidence 0.35 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
SU11248 (sunitinib malate) is an inhibitor of receptor tyrosine kinases for VEGFR1, VEGFR2, PDGFR, c-kit, and Flt-3.
Negative_regulation (inhibitor) of VEGFR1
7) Confidence 0.31 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.69 Pain Relevance 0.03
Cediranib (AZD2171, Recentin) is a potent inhibitor of both VEGFR-1 and VEGFR-2; it also has activity against c-kit, PDGFR-?
Negative_regulation (inhibitor) of VEGFR-1
8) Confidence 0.29 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.75 Pain Relevance 0
Cediranib (AZD2171, Recentin) is a potent inhibitor of both VEGFR-1 and VEGFR-2; it also has activity against c-kit, PDGFR-?
Negative_regulation (inhibitor) of VEGFR-2
9) Confidence 0.29 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.76 Pain Relevance 0
Thus both classical and atypical neuroleptics were effective in prolonging HRT, whereas only the classical neuroleptics prolonged FRT (criterion 1); the nonneuroleptic phenothiazine promethazine (as well as the narcotic morphine, the muscle relaxant diazepam and the antidepressant desipramine) were ineffective in this respect (criterion 2); the acetylcholinergic antagonist scopolamine blocked the FRT, but not the HRT (criterion 3); chronic neuroleptic treatment reduced the FRT, but not the HRT (criterion 4).
Negative_regulation (reduced) of FRT in muscle associated with desipramine, antidepressant, antagonist and morphine
10) Confidence 0.26 Published 1988 Journal Life Sci. Section Abstract Doc Link 2894605 Disease Relevance 0.14 Pain Relevance 0.24
Thus both classical and atypical neuroleptics were effective in prolonging HRT, whereas only the classical neuroleptics prolonged FRT (criterion 1); the nonneuroleptic phenothiazine promethazine (as well as the narcotic morphine, the muscle relaxant diazepam and the antidepressant desipramine) were ineffective in this respect (criterion 2); the acetylcholinergic antagonist scopolamine blocked the FRT, but not the HRT (criterion 3); chronic neuroleptic treatment reduced the FRT, but not the HRT (criterion 4).
Negative_regulation (blocked) of FRT in muscle associated with desipramine, antidepressant, antagonist and morphine
11) Confidence 0.26 Published 1988 Journal Life Sci. Section Abstract Doc Link 2894605 Disease Relevance 0.14 Pain Relevance 0.24
The decrease in FLT uptake as seen in the first week was followed by a much larger decrease in the second week, which was not the case for FDG uptake.
Negative_regulation (decrease) of FLT
12) Confidence 0.25 Published 2007 Journal Mol Imaging Biol Section Body Doc Link PMC2040178 Disease Relevance 0.43 Pain Relevance 0
Vatalanib is a pan-VEGFR tyrosine kinase inhibitor with activity against VEGFR-1, VEGFR-2 and VEGFR-3.
Negative_regulation (inhibitor) of VEGFR-1
13) Confidence 0.25 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.63 Pain Relevance 0.03
Tolfenamic acid, a nonsteroidal anti-inflammatory drug, decreases Sp protein expression in Panc-1 and L3.6pl pancreatic cancer cells, and this was accompanied by decreased VEGFR1 protein and mRNA and decreased luciferase activity on cells transfected with constructs (pVEGFR1) containing VEGFR1 promoter inserts.
Negative_regulation (decreased) of VEGFR1 protein associated with inflammation, pancreatic cancer and cinod
14) Confidence 0.23 Published 2007 Journal Cancer Res. Section Abstract Doc Link 17409437 Disease Relevance 0.72 Pain Relevance 0.10
Thus, targeted degradation of Sp proteins is highly effective for inhibiting VEGFR1 and associated angiogenic responses in pancreatic cancer.
Negative_regulation (inhibiting) of VEGFR1 associated with pancreatic cancer
15) Confidence 0.23 Published 2007 Journal Cancer Res. Section Abstract Doc Link 17409437 Disease Relevance 0.61 Pain Relevance 0.06
Angiozyme inhibits angiogenesis by selectively downregulating VEGFR1 through targeted cleavage of VEGFR1 mRNA [116].
Negative_regulation (downregulating) of VEGFR1 in cleavage
16) Confidence 0.21 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 0.69 Pain Relevance 0
The low levels of Ang-(1–7) and ACE2 in the RUPP model may represent an inhibition of the vasodilator arm of the renin-angiotensin system associated with factors generated by the reduced placental blood flow (sFlt-1, TNF-?
Negative_regulation (inhibition) of sFlt-1 in blood
17) Confidence 0.16 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2739214 Disease Relevance 0.08 Pain Relevance 0
Increasing direct clearance from blood (kCL) drastically lowered free VEGF and sVEGFR1 concentrations in plasma (Fig. 10).
Negative_regulation (lowered) of sVEGFR1 in plasma
18) Confidence 0.15 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Vatalanib is a multitargeted tyrosine kinase inhibitor targeting angiogenesis that inhibits PDGFRB, VEGFR1, VEGFR2, c-Kit, and c-Fms.
Negative_regulation (inhibits) of VEGFR1 associated with fibromyalgia
19) Confidence 0.15 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.73 Pain Relevance 0.03
VEGFR Tyrosine Kinase Inhibitors

Cediranib (AZD2171, CED) is a highly selective and potent oral tyrosine kinase inhibitor (TKI) of VEGFR1, VEGFR2, VEGFR3, and c-Kit.

Negative_regulation (inhibitor) of VEGFR1 associated with camurati-engelmann disease
20) Confidence 0.15 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 2.16 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox